The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Eli Lilly said a Phase 2 clinical trial for its treatment to inhibit lipoprotein(a) formation met its primary endpoint. Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...